¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"One Touch Glucose Low Control InVt"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • safety control
    ¾ÈÀü°ü¸®
  • self-control disorder
    ÀÚ±âÁ¶ÀýÀå¾Ö
  • sensitivity control
    °¨µµÁ¶Á¤±â, °¨µµÁ¶Àý
  • sibling control
    ÇüÁ¦´ëÁ¶±º
  • venereal disease control
    ¼ºº´°ü¸®
  • vestibuloequilibratory control
    ¾È¶ãÆòÇü±â´ÉÁ¶Àý, ÀüÁ¤ÆòÇü±â´ÉÁ¶Àý
  • voice-activated control
    À½¼ºÀÛµ¿Á¶Àý
  • volitional control
    ÀÇÁöÀûÅëÁ¦
  • weight control program
    üÁßÁ¶Àý°èȹ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • tumor control
    Á¾¾ç¾ïÁ¦
  • venereal disease control
    ¼ºº´°ü¸®
  • vestibuloequilibratory control
    ¾È¶ãÆòÇü±â´ÉÁ¶Àý
  • voice-activated control
    À½¼ºÀÛµ¿Á¶Àý
  • volitional control
    ÀÚ¹ßÀûÅëÁ¦
  • water pollution control
    ¼öÁú¿À¿°°ü¸®
  • water quality control
    ¼öÁú°ü¸®
  • impulse control disorder
    Ãæµ¿Á¶ÀýÀå¾Ö, Ãæµ¿Á¶Àýº´
  • self-control disorder
    ÀÚ±âÁ¶ÀýÀå¾Ö
  • gate control system
    °ü¹®Á¶Á¤ÀåÄ¡
  • gate-control theory
    ¹®Á¶ÀýÀÌ·Ð
  • head control
    ¸Ó¸®°¡´©±â
  • infection control study
    °¨¿°°ü¸®Á¶»ç
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • leprosy control program
    ³ªº´°ü¸®»ç¾÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • low birth weight infant
    ÀúüÁßÃâ»ý¾Æ.
  • low birth wight infant
    ÀúüÁßÃâ»ý¾Æ(î¸ô÷ñìõóßæä®)
  • low blood pressure
    ÀúÇ÷¾Ð(î¸úìäâ).
  • low caloric diet
    ÀúÄ®·Î¸®½Ä.
  • low cardiac output syndrome
    Àú½É¹ÚÃâÁõÈıº.
  • low cervical cesarean section
    ÇÏ(ºÎ)ÀڱðæºÎÁ¦¿ÕÀý°³¼ú(ù»(Ý»)í­ÏàÌò Ý»ð¨èÝôîËÒâú) .
  • low cholesterol diet
    ÀúÄÝ·¹½ºÅ×·Ñ½Ä (­ãÝ).
  • low colostomy
    ÀúÀ§°áÀåÁ¶·ç¼ú(ÀúÀ§°áÀåÁ¶·ç¼ú).
  • low cost food plan
    ¿°°¡½Ä»ç°èȹ.
  • low delirium
    ¼ÒÁø¼º Çê¼Ò¸®.
  • low density lipoprotein
    Àú¹ÐµµÁö´Ü¹é
  • low density lipoprotein =LDL
    Àú¹ÐµµÁö´Ü¹é.
  • low density lipoprotein =LDL
    Àú¹ÐµµÁö´Ü¹éÁú.
  • low dose
    Àú¼±·®
  • low dose rate
    Àú¼±·®À²
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
mrhm milliroentgens per hour at one meter
P1, P-one first parental generation
PL/I programming language I (one)
sem one-half [Lat. semis]; semen, seminal
SOLEC stand on one leg eyes closed
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
CO Control
CON Control
CONT Control
CTL Control
CTR Control
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
glucose intolerance A pathological state in which the fasting plasma glucose level is less than 140 mg per deciliter and the 30-, 60-, or 90-minute plasma glucose concentration following a glucose tolerance test exceeds 200 mg per deciliter. This condition is seen frequently in diabetes mellitus but also occurs with other diseases.
(12 Dec 1998)
glucose isomerase <enzyme> An isomerase enzyme which converts the sugar glucose into the sugar fructose. Fructose is a structural isomer of glucose.
(09 Oct 1997)
glucose oxidase <enzyme> An enzyme which converts glucose into gluconic acid and hydrogen peroxide (H2O2). It is used to help diagnose diabetes by determining if glucose is present in the patients urine, if the glucose is present, the hydrogen peroxide produced in the reaction can be detected by reacting it with an indicator to change the colour of the urine.
(09 Oct 1997)
glucose oxidase method <chemical pathology> A highly specific method for measurement of glucose in serum or plasma by reaction with glucose oxidase, in which gluconic acid and hydrogen peroxide are formed.
(05 Mar 2000)
glucose oxidase paper strip test <chemical pathology> A qualitative test for glucose in the urine, in which glucose is oxidised to gluconic acid by glucose oxidase; a specific test, unless ascorbic acid is present.
(05 Mar 2000)
glucose oxyhydrase <enzyme> An enzyme which converts glucose into gluconic acid and hydrogen peroxide (H2O2). It is used to help diagnose diabetes by determining if glucose is present in the patients urine, if the glucose is present, the hydrogen peroxide produced in the reaction can be detected by reacting it with an indicator to change the colour of the urine.
(09 Oct 1997)
glucose-phosphate isomerase <enzyme> An enzyme that catalyses the reversible interconversion of d-fructose 6-phosphate and d-glucose-6-phosphate; a part of glycolysis and gluconeogenesis; glucosephosphate isomerase deficiency is an inherited disorder resulting in liver glycogenesis and haemolytic anaemia.
Synonym: hexosephosphate isomerase, phosphohexomutase, phosphohexose isomerase.
(05 Mar 2000)
glucose phosphomutase <enzyme> An enzyme that catalyses the conversion of alpha d-glucose 1-phosphate to alpha d-glucose-6-phosphate.
Chemical name: alpha-D-Glucose 1,6-phosphomutase
Registry number: EC 5.4.2.2
(12 Dec 1998)
glucose related protein <protein> One of the stress related proteins: identical to endoplasmin.
(18 Nov 1997)
glucose solution, hypertonic Solution that is usually 10 percent glucose but may be higher. An isotonic solution of glucose is 5 percent.
(12 Dec 1998)
glucose tolerance factor A water-soluble complex containing chromium needed for normal glucose tolerance.
(05 Mar 2000)
glucose tolerance test <chemical pathology, investigation> A special test where the blood glucose is measure in intervals after a glucose-rich meal is taken, a test used for diagnosing diabetes.
(27 Sep 1997)
glycerol-3-phosphate - glucose phosphotransferase <enzyme> Catalyses the formation of glycerol and glucose-6-phosphate
Registry number: EC 2.7.1.142
Synonym: gro3p-glucose transphorylase, glycerol 3-phosphate-glucose transphorylase
(26 Jun 1999)
phosphoenolpyruvate-glucose phosphotransferase <enzyme> Specific for glucose and nonmetabolizable analogs methyl alpha glucoside, beta-d-thioglucose and 5-thioglucose
Registry number: EC 2.7.1.-
Synonym: II-b(glc) peppts, enzyme II-b(glc) phosphoenolpyruvate phosphotransferase system, enzyme II (glucose), glucose-specific permease, phosphotransferase system, beta-glucosidase permease, beta-glucoside permease, glucose permease, enzyme II(glc), bglp gene product, syta gene product
(26 Jun 1999)
deficiency, glucose-6-phosphate dehydrogenase Deficiency of G6PD is the commonest disease-causing enzyme defect in humans affecting an estimated 400 million people. The G6PD gene is on the X chromosome. Males with the enzyme deficiency develop anaemia due to breakup of their red blood cells when they are exposed to oxidant drugs such as the antimalarial primaquine, the sulfonamide antibiotics or sulfones, naphthalene moth balls, or fava beans.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • fingertip control
    ¹öư Á¶Á¾(ÀåÄ¡)
  • fire control
    »ç°ÝÁöÈÖ
  • fire control radar
    È­±â °üÁ¦ ·¹ÀÌ´õ
  • flight control
    °üÁ¦¼Ò
  • flood control
    Ä¡¼ö
  • food control
    ½Ä·® °ü¸®(ºñ»ó½ÃÀÇ)
  • fourpenny one
    °­Å¸
  • gain control
    (ÀüÀÚ)(¼ö½Å±â,Á߯ø±âÀÇ)À̵æ Á¦¾î
  • ground control
    (ºñÇàÀåÀÇ)Áö»ó °üÁ¦(°ü)
  • light control
    µîÈ­ °üÁ¦
  • loved one
    ½Ã½Å;ÁÖ°Ë
  • mission control
    (Áö»óÀÇ) ¿ìÁÖ ºñÇà °üÁ¦ ¼¾ÅÍ
  • no one,noone
    ¾Æ¹«µµ..¾Ê´Ù(nobody)
  • number one
    (No.1)Á¦ 1È£(¹ø)Á¦ 1ÀÎÀÚ;Áß½ÉÀι°;ÀÚ±â;ÀÚ±âÀÇ ÀÌÇØ;¿ÀÁÜ;¼Òº¯;Á¦1ÀÇ ÀÏ·ùÀÇ ÃÖ°íÀÇ
  • number one boy
    (¹Ì±¸)±Ç·ÂÀÚ;»çÀå;¹ÏÀ»¼ö ÀÖ´Â º¸Á¿ª;YES MEN
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á